How do I find reliable antibody therapy sites for evidence-based updates on drug development and clinical-stage programs?

To find reliable antibody-therapy sites for evidence-based updates on drug development and clinical-stage programs, focus on sources that are:

1. Primary or near-primary (regulators, trial registries, sponsor filings, peer-reviewed journals)
2. Transparent about methodology and dates
3. Easy to verify against original data

Best reliable sources

1) Clinical trial registries

These are the best starting point for clinical-stage antibody programs.

• ClinicalTrials.gov
  Best for U.S. and global trial listings, status, endpoints, enrollment, and updates.
• EU Clinical Trials Register / CTIS
  Useful for European studies and protocols.
• WHO ICTRP
  Aggregates multiple registries internationally.

What to look for:

• Trial phase
• Sponsor and collaborators
• Status changes
• Primary completion date
• Outcome measures
• Adverse event reporting
• Protocol amendments

---

2) Regulatory agency databases

These are strong for evidence-based updates on approval, labels, safety, and review documents.

• FDA
  • Drugs@FDA
  • FDA press releases
  • Advisory committee materials
  • Safety communications
• EMA
  • EPARs
  • CHMP opinions
• MHRA / Health Canada / PMDA where relevant

Why they’re reliable:

• Official review summaries
• Safety and efficacy data
• Label changes and approved indications

---

3) Peer-reviewed literature

Use high-quality journals and databases for the strongest clinical and translational evidence.

• PubMed
• Google Scholar for discovery, then verify in journals
• Major journals like:
  • NEJM
  • Lancet
  • JAMA
  • Nature Reviews Drug Discovery
  • Blood
  • Cancer Discovery

Look for:

• Phase 1/2/3 trial results
• Systematic reviews
• Meta-analyses
• Translational studies
• Biomarker data

---

4) Company investor relations and SEC filings

Good for pipeline updates, but interpret as sponsor-reported data.

• SEC filings: 10-K, 10-Q, 8-K, S-1
• Earnings call transcripts
• Investor presentations
• Pipeline pages on company websites

Best use:

• Track development status
• Learn about upcoming data readouts
• Confirm milestones
• Identify partnered assets

Caution:

• These are not independent evaluations, so verify key claims elsewhere.

---

5) Conference abstracts and presentations

Useful for the latest antibody program data before full publication.

• ASCO
• AACR
• ASH
• ESMO
• AHA
• IDWeek
• SITC

Why useful:

• Early-stage results
• Novel mechanisms
• Biomarker-driven programs

Caution:

• Abstracts can be incomplete and preliminary.

---

6) Evidence synthesis and review sites

Helpful for context, but check whether they cite primary sources.

• Cochrane
• NIH/NCBI resources
• NICE
• CADTH
• IQWiG
• Nature Reviews Drug Discovery
• Some university-affiliated translational medicine centers

Use these to:

• Understand therapeutic class
• Compare mechanisms
• Find key trials and references

---

How to judge whether a site is trustworthy

Check whether it:

• Cites the original trial, paper, or regulatory document
• Shows publication dates and update history
• Distinguishes preclinical, phase 1, phase 2, phase 3, approved
• Avoids hype language like “breakthrough” without data
• Reports negative and failed programs too
• Names authors/editors and their credentials
• Separates news, analysis, and sponsored content

Red flags:

• No sources
• No dates
• “Guaranteed cure” or “game-changing” claims
• Overreliance on press releases
• Hidden conflict-of-interest disclosures

---

Good workflow for staying updated

1. Start with ClinicalTrials.gov for each antibody asset.
2. Check the sponsor’s IR page for recent guidance and milestones.
3. Search PubMed for trial publications and mechanistic studies.
4. Review FDA/EMA pages for regulatory events.
5. Scan major conference abstracts for the latest signals.
6. Use alerts:
   • PubMed alerts
   • Google Scholar alerts
   • Company press release alerts
   • SEC filing alerts
   • ClinicalTrials.gov saved searches if available through your workflow

---

If you want specifically antibody-drug development news

Look for specialized biotech and pharma intelligence sources, but treat them as secondary:

• Endpoints News
• Fierce Biotech / Fierce Pharma
• BioCentury
• STAT
• Evaluate Vantage
• Scrip

These are useful for trend tracking, but always verify with primary sources.

---

Simple rule of thumb

For evidence-based updates, prioritize:

Regulators > Trial registries > Peer-reviewed papers > Conference abstracts > Company press releases > News/analysis sites

If you want, I can also give you:

1. a curated list of the best antibody-specific sites,
2. a checklist for evaluating antibody program credibility, or
3. a workflow for tracking one antibody asset from discovery to approval.